Provided by Tiger Trade Technology Pte. Ltd.

Faeth Therapeutics

29.74
+1.675.95%
Post-market: 29.740.00000.00%19:30 EDT
Volume:356.52K
Turnover:10.46M
Market Cap:766.66M
PE:-0.21
High:30.18
Open:28.49
Low:27.67
Close:28.07
52wk High:42.14
52wk Low:7.45
Shares:25.78M
Float Shares:811.70K
Volume Ratio:0.98
T/O Rate:43.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-141.6499
EPS(LYR):-16.7239
ROE:-195.26%
ROA:-20.79%
PB:4.43
PE(LYR):-1.78

Loading ...

U.S. Research Roundup-Health Catalyst, Nektar Therapeutics, TIC Solutions

Reuters
·
Aug 21

U.S. Stocks on the MOVE - Sunrun, JetBlue Airways, Dell Technologies

Reuters
·
Aug 17

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for Piktor Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Reuters
·
Aug 17

Faeth Therapeutics - Topline Data from Phase 2 Trial in Advanced Endometrial Cancer Expected by Year-End 2026

THOMSON REUTERS
·
Aug 17

Faeth Therapeutics - Interim Data from Phase 1B/2 Trial in Advanced Breast Cancer Expected in 2027

THOMSON REUTERS
·
Aug 17

Faeth Therapeutics Names Deepak Tiwari SVP of Technical Operations

Reuters
·
Aug 14

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

THOMSON REUTERS
·
Aug 14

Faeth Therapeutics Price Target Maintained with a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 11

Faeth Therapeutics Grants New-Hire Stock Options for 11,000 Shares at $25.5 Each

Reuters
·
Aug 08

Faeth Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Faeth Therapeutics Presents PK/PD Modeling Supporting Piktor Dose in Phase 2 Endometrial Cancer Trial FTH-PIK-201

Reuters
·
Aug 07

Faeth Therapeutics management to meet with BTIG

TIPRANKS
·
Aug 05

Faeth Therapeutics, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Faeth Therapeutics initiated with a Buy at JonesResearch

TIPRANKS
·
Aug 04

Faeth Therapeutics, Inc : Jonestrading Initiates Coverage with Buy Rating; Target Price $55

THOMSON REUTERS
·
Aug 04

Faeth Therapeutics reports Q2 EPS ($2.84) vs ($3.91) last year

TIPRANKS
·
Aug 04

Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate

Benzinga Earnings
·
Aug 04

Faeth Therapeutics Q2 FY26 Net Loss Widens to $16.01 Million

Reuters
·
Aug 04

Press Release: Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

Dow Jones
·
Aug 04

U.S. Research Roundup-Cloudflare, Replimune, Walmart

Reuters
·
Aug 04